A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Advanced Cancer

About this trial
This is an interventional treatment trial for Advanced Cancer
Eligibility Criteria
Inclusion Criteria:
The one who meet all inclusion criteria can be enrolled into the trial:
- Sign Informed Consent Form voluntarily. Understand the study and be willing to follow and be able to complete all trial procedures;
- Male or female aged at 18-75 (inclusive) years when ICF is signed;
Suffer from advanced unresectable or metastatic malignant local solid tumors confirmed by histological diagnosis and meet the criteria of the enrolled group as follows:
Part I: Mono-therapy dose escalation and expansion study:
Mono-therapy dose escalation study: The subjects for whom no standard treatment regimens are available or who is intolerable to standard treatments.
Mono-therapy dose expansion study: The subjects with positive CDLN18.2 expression in tumor tissue (which is defined as ≥40% tumor cells showing CLDN18.2 membrane dye ≥2+ through immunohistochemistry (IHC) test by the central laboratory) confirmed by the central laboratory at enrollment. There are 2 groups in Part I as follow:
Group A: The subjects with G/GEJ adenocarcinoma for whom no standard therapy regimens are available currently or who are intolerable to standard therapy regimens; Group B: The subjects with other malignant tumors (including but not limited to ductal adenocarcinoma of pancreas, bile duct carcinoma, lung cancer, ovarian carcinoma and other malignant solid tumors) for whom no standard therapy regimens are available currently or who are intolerable to standard therapy regimens; Part II: Dose escalation and expansion study of combination medication
Dose escalation study of combination medication (dose escalation part):
Group C: The subjects with HER2 negative G/GEJ adenocarcinoma without previous systemic chemotherapy. The subjects who have completed neoadjuvant chemotherapy or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study are allowed to be enrolled.
Group D: The subjects with G/GEJ adenocarcinoma at least with previous first-line systemic chemotherapy;
Dose expansion study of combination medication (dose expansion part):
The subjects with CDLN18.2 positive solid tumors (which is defined as ≥40% tumor cells showing CLDN18.2 membrane dye≥2+ through immunohistochemistry (IHC) test by the central laboratory) confirmed by the central laboratory will be enrolled.
Group C: The subjects with HER2 negative G/GEJ adenocarcinoma without previous systemic chemotherapy. The subjects who have completed neoadjuvant chemotherapy or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study are allowed to be enrolled.
Group D: The subjects with G/GEJ adenocarcinoma at least with previous first-line systemic chemotherapy; During the study, additional groups for the treatment of other solid tumors might be added according to the available clinical and pre-clinical study data (the inclusion criteria is to be determined).
- ECOG score 0-1;
- Expected survival ≥ 3 months;
The results of the laboratory examination at screening must meet all the following criteria:
Absolute neutrophil count (ANC) ≥ 1.5×109/L; Absolute count (WBC) ≥ 2.5×109/L; Platelets ≥ 100×109/L; Haemoglobin ≥ 9 g/dL; International normalized ratio (INR) ≤ 1.5 times Upper Limit of Normal (ULN) / or activated partial thromboplastin time (APTT) ≤ 1.5 times ULN (for the test without anticoagulant); INR ≤ 2.5 times ULN / or APTT ≤ 2.5 times ULN (for the test with anticoagulant); Total Bilirubin ≤ 1.5 times ULN; AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for the subjects with hepatic cancer or metastases to liver); Albumin ≥ 3.0 g/L; Serum creatinine ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60 ml/min (creatinine clearance rate will be calculated by Cock-croft-Gault formula);
- Male and female of childbearing age should agree to take effective contraception measures (refer to Appendix 3. Contraception) from signing ICF till 3 months after the last dose; Blood β-HCG test for women of childbearing age within 70 hours prior to the initial dosing must be negative;
- (For dose expansion study only) There must be at least one assessable lesion conforming to the definition in RECIST v1.1;
Exclusion Criteria:
The subjects who meet any one of the following criteria cannot participate in the study:
- The subjects with advanced unresectable or metastatic local G/GEJ adenocarcinoma who are supposed to be enrolled into the combination therapy group with CAPOX have previously received systemic chemotherapy. The subjects will be eligible provided that they have completed neoadjuvant chemotherapy or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study; The subjects with advanced unresectable or metastatic local G/GEJ adenocarcinoma who are supposed to be enrolled into the combination therapy with paclitaxel have previously received paclitaxel treatment.
- The subjects who received radiotherapy within 4 weeks prior to the initial dosing of the investigational drug (the subjects who received local radiotherapy for bone metastases treatment with the radiotherapy related AE resolved to ≤ Grade 1 will be eligible);
- The subjects who received other anti-tumor medication or radiotherapy within 4 weeks prior to the initial dosing of the investigational drug; The medication (such as Zoledronic Acid) for bone metastases related events will not influence on the enrollment.
- The subjects who received major surgery (exclusive of aspiration biopsy) within 8 weeks prior to the initial dosing of the investigational drug, or who are expected to undergo major surgery, or who are in the conditions such as severe unhealed wound, trauma, ulcer.
- The subjects who received the treatment with CLDN18.2 monoclonal antibody or CLDN-18.2CART;
- The subjects who have previous serious allergic reactions, or are intolerable to the known component of TST001 or other monoclonal antibodies (including humanized or chimeric antibodies);
- The subjects who are known to have immediate or delayed hypersensitivity to, be intolerable to or be forbidden from any component of the investigational drugs;
- The subjects who have previous serious allergic reaction or intolerance to any component of CAPOX or taxane drugs;
The subjects who manifest the symptoms of brain or leptomeningeal metastases;
The subjects with central nerve system (CNS) metastasis who meets the following conditions can be enrolled:
The subjects with brain metastasis who are naive to any treatment and have no symptom, or who are in progressive free status persisting for at least 8 weeks after treatment demonstrated by imaging data and do not require hormone or anti epilepsy treatment at least within 8 weeks;
- The subjects suffering from body cavity effusion (hydrothorax, ascites and pericardial effusion) that requires local treatment or repeated drainage and is not well controlled at the discretion of the investigator;
- (For dose expansion study only) The subjects suffering from co-existent malignant tumors. (The following tumor history at 5 years ago that has been cured will not influence on the enrollment: non-melasma, skin carcinoma, in situ cancer or non-invasive tumors.)
- The adverse reactions caused by previous treatment have not resolved to ≤ Grade 1 as per CTCAE v5.0 (exclusive of alopecia and anaemia) before the initial dosing of the investigational drug. If the adverse reaction has no clinical influence, the Sponsor and investigator will decide whether the subject can be enrolled in the study after discussion.
- The subjects who received growth factor, transfusion or other blood products in treatment of anaemia or decreased platelet within 14 days before screening;
The subjects who experienced clinically significant cardiac diseases within 6 months before the initial dosing of the investigational drug, including:
i. Myocardial infarction, ii. Unstable angina pectoris, iii. Cerebrovascular accident or iv. Other acute and uncontrollable cardiac diseases; Clinically significant ventricular arrhythmia history (such as persisting ventricular tachycardia, ventricular fibrillation and torsade de pointes); New York Heart Association (NYHA) Class III or IV congestive cardiac failure; QTc ≥470 (female) or QTc ≥450 (male) or medical history or family history of congenital long-QT syndrome ; The subjects with heart rhythm disorders who requires the treatment with antiarrhythmic drugs (The subjects who suffer from atrial fibrillation with heart rate controllable more than 1 month before the initial dosing of the investigational drug will be eligible);
- . The subjects who are known to have dihydropyrimidine dehydrogenase (DPD) deficiency. (Note: DPD deficiency screening should be performed according to local standard.) (The screening will be performed only in the subjects receiving CAPOX.)
- The subjects who experienced gastric haemorrhage recently or have the risk of gastric haemorrhage or gastric perforation demonstrated by evidences will be excluded from the study at the discretion of the investigator. The subjects suffering from obstruction pyloric and persistent repeated vomiting;
- The subjects who are known to have > Grade 1 peripheral sensory neuropathy, unless a lack of deep tendon reflexes is the only neurological abnormality.
- The subjects suffering from serious or uncontrollable gastro-intestinal tract bleed;
- The subjects suffering from active infection requiring systemic treatment;
- The subjects who have HIV infection history or positive HIV viral test;
The subjects who are known to have the history of hepatitis C or chronic active hepatitis B;
Except for:
HBV virus carriers or the subjects with hepatitis B infection that is stable after medications (HBV-DNA titer should be no more than 1000 copies [cps]/mL or 200 IU/mL) The subjects with hepatitis C infection that is stable after medications (HCV-RNA test negative)
- The subjects suffering from active autoimmune disorders who required systemic immunosuppressive therapy within the past 2 years;
- The subjects who received systemic immunosuppressive therapy including glucocorticoid within 2 weeks before the initial dosing of the investigational drug; The subjects will be allowed to use hydrocortisone or similar drugs at physiologically alternative dose;
- Pregnant or lactating women;
- The subject with other conditions (such as psychological, geographic or medical conditions) that do not allow them to follow the study schedule and follow-up procedures. Or the subjects who are unsuitable to be enrolled into the study at the discretion of the investigator.
Sites / Locations
- The First Affiliated Hospital of Bengbu Medical CollegeRecruiting
- Beijing Cancer HospitalRecruiting
- Beijing Friendship Hospital, Capital Medical UniversityRecruiting
- Peking Union Medical College Hospital
- Peking University International Hospital
- The First Affiliated Hospital of Chongqing Medical UniversityRecruiting
- Fujian Cancer HospitalRecruiting
- Fujian Medical University Union HospitalRecruiting
- The First Affiliated Hospital of Xiamen UniversityRecruiting
- The Sixth Affiliated Hospital of Sun Yat-sen UniversityRecruiting
- The People's Hospital of Guangxi Zhuang Autonomous Region
- Hainan Provincial People's HospitalRecruiting
- The First Affiliated Hospital of Zhengzhou UniversityRecruiting
- Harbin Medical University Cancer HospitalRecruiting
- Henan Cancer HospitalRecruiting
- Hubei Cancer HospitalRecruiting
- Zhongnan Hospital of Wuhan UniversityRecruiting
- Hunan Cancer HospitalRecruiting
- Xiangya Hospital, Central South UniversityRecruiting
- Suzhou Municipal HospitalRecruiting
- The Second Affiliated Hospital of Soochow UniversityRecruiting
- Xuzhou Central HospitalRecruiting
- The Second Affiliated Hospital of Nanchang UniversityRecruiting
- Jilin Cancer HospitalRecruiting
- The First Hospital of Jilin UniversityRecruiting
- The First Affiliated Hospital of Jinzhou Medical UniversityRecruiting
- Liaoning Cancer Hospital & InstituteRecruiting
- The First Hospital of China Medical UniversityRecruiting
- Jinan Central HospitalRecruiting
- Linyi Cancer HospitalRecruiting
- The Affiliated Hospital of Qingdao UniversityRecruiting
- Fudan University Shanghai Cance CenterRecruiting
- Zhongshan Hospital Fudan UniversityRecruiting
- West China Hospital, Sichuan UniversityRecruiting
- Sichuan Cancer HospitalRecruiting
- Tianjin Medical University Cancer Institute & HospitalRecruiting
- Tianjin Medical University General HospitalRecruiting
- First Affiliated Hospital of Zhejiang UniversityRecruiting
- The Second Affiliated Hospital of Zhejiang University School of MedicineRecruiting
- Zhejiang Cancer HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
dose escalation Q2W
dose escalation Q3W
Cohort A
Cohort B
Cohort E
Cohort C
Cohort D
Cohort F
Cohort G
Cohort H (TST001 plus nivolumab)
Dosed every 2 weeks IV with TST001, multiple dose levels will be tested.
Dosed every 3 weeks IV with TST001, multiple dose levels will be tested.
Participants with gastric or gastroesophageal junction cancers and CLDN18.2 expression
Participants with ductal adenocarcinoma of pancreas and CLDN18.2 expression and CLDN18.2 expression
Participants with advanced or metastatic solid tumors other than G/GEJ adenocarcinoma and CLDN18.2 expression
Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma
Participants with locally advanced or metastatic G/GEJ adenocarcinoma
Participants with locally advanced or metastatic biliary tract cancer
Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma
Participants with locally advanced or metastatic G/GEJ adenocarcinoma